Cargando...
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
OBJECTIVE: Our objective was to evaluate the cost effectiveness of the combination of nivolumab and ipilimumab, referred to as “Regimen”, as a first-line treatment for patients with advanced melanoma from the perspective of Canada’s public healthcare system. METHODS: We developed a partitioned-survi...
Gardado en:
| Publicado en: | Pharmacoecon Open |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710483/ https://ncbi.nlm.nih.gov/pubmed/30617952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0112-1 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|